Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil
Abstract
Authors
A.M. Nishikawa L. Paladini A.L. Liamas C.C. Bueno O.A.C. Clark